接受肾脏替代治疗的终末期肾病ANCA相关性血管炎患者的结局:一项荟萃分析
该荟萃分析纳入22项研究共952例接受血液透析或腹膜透析的ANCA相关性血管炎合并终末期肾病成人患者,汇总死亡率为每100人年10.90(95%CI 7.11-14.68),1年生存率80.9%、5年生存率61.0%,严重感染率每100人年66.57,复发率每100人年6.22;作者认为此类患者复发风险较低但感染和死亡率较高,需更多前瞻性研究探讨终末期肾病后免疫抑制的作用。
要点
- 合并终末期肾病的ANCA相关性血管炎患者汇总死亡率为每100人年10.90(95%CI 7.11-14.68)。
- 汇总1年生存率80.9%(95%CI 75.6-86.1%),5年生存率61.0%(95%CI 46.0-76.0%)。
- 汇总严重感染率每100人年66.57(95%CI 13.64-119.50),复发率每100人年6.22(95%CI 4.64-7.80)。
核心结论
- 合并终末期肾病的ANCA相关性血管炎患者复发风险较低,但感染和死亡率较高。
- 需要更多前瞻性研究探讨终末期肾病后免疫抑制的作用。
研究设计与样本
- 检索MEDLINE和Embase数据库,检索时间从建库至2021年12月。
- 纳入任何报告接受血液透析或腹膜透析的ANCA相关性血管炎合并终末期肾病患者结局的研究。
- 共发现2470条引文,最终纳入22项研究共952例成人患者,随访超过3600人年。
- 主要结局为采用随机效应荟萃分析模型计算的每100人年死亡率。
- 感染率和复发率为次要结局。
主要发现
- 汇总死亡率为每100人年10.90(95%CI 7.11-14.68,I²=90.8%)。
- 汇总1年生存率为80.9%(95%CI 75.6-86.1%,I²=86.1%),汇总5年生存率为61.0%(95%CI 46.0-76.0%,I²=0.0%)。
- 汇总严重感染率为每100人年66.57(95%CI 13.64-119.50,I²=99.6%)。
- 汇总复发率为每100人年6.22(95%CI 4.64-7.80,I²=46.6%)。
- 仅1项儿科研究符合纳入标准,报告9例患者中死亡率为每100人年11.7±1.9例死亡(95%CI 0.23-23.20)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 汇总死亡率的异质性I²=90.8%。
- 汇总1年生存率的异质性I²=86.1%。
- 汇总严重感染率的异质性I²=99.6%。
- 汇总复发率的异质性I²=46.6%。
- 仅1项儿科研究符合纳入标准并报告了9例患者的死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: End-stage kidney disease (ESKD) is associated with poor prognosis in patients with anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This study summarizes the existing evidence regarding outcomes in AAV patients with ESKD on renal replacement therapy. METHODS: Searches of the MEDLINE and Embase databases were performed from inception until December 2021. Any study reporting outcomes after ESKD in patients with AAV on haemodialysis or peritoneal dialysis was included. The mortality rate per 100 person-years (100 py) calculated with a random-effects meta-analysis model was the primary outcome. Rates of infections and relapses were secondary outcomes. RESULTS: 2470 citations were found; 22 studies of 952 adult patients with over 3600 person-years of follow-up were included. The pooled mortality rate was 10.90 per 100 py (95% CI: 7.11 - 14.68, I2 = 90.8%). The pooled 1-year survival was 80.9% (95% CI: 75.6 - 86.1%, I2 = 86.1%) while the pooled 5-year survival was 61.0% (95% CI: 46.0 - 76.0%, I2 = 0.0%). The pooled severe infection rate was 66.57 per 100 py (95% CI: 13.64 - 119.50, I2 = 99.6%). The pooled relapse rate was 6.22 per 100 py (95% CI: 4.64 - 7.80, I2 = 46.6%). Only 1 paediatric study met the inclusion criteria and reported a mortality rate of 11.7 ± 1.9 deaths per 100 py (95% CI: 0.23 - 23.20) amongst 9 patients. CONCLUSIONS: Patients with AAV and ESKD have a lower risk of relapse, but higher infection and mortality rates. More prospective research exploring the role of immunosuppression after ESKD is needed.
引用
- Pope V, Sivashanmugathas V, Moodley D, et al. Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy-A meta-analysis. Semin Arthritis Rheum. 2023. PMID: 36931168. doi:10.1016/j.semarthrit.2023.152189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。